patients enrolled in the study were closely monitored for symptoms or signs of clotting or bleeding and underwent an x-ray of the veins of the operated leg to detect any possible clot formation.
abelacimab’s potential to treat other cardiovascular conditions has weitz and his fellow scientists excited.
“this success of abelacimab in this study provides the foundation for its use for prevention of stroke in patients with atrial fibrillation and for treatment of deep-vein thrombosis and pulmonary embolism, clots in the veins of the leg and clots in the lung, in patients with cancer,” said weitz.
abelacimab is an antibody that binds to both the inactive and activated forms of factor xi, one of the clotting factors, and prevents its activation and activity, thereby halting clot formation.
the study proved that factor xi is a key driver of clot formation after surgery, weitz said, adding that the fact that abelacimab was more effective than enoxaparin, which inhibits clotting factors downstream to factor xi, highlights the importance of factor xi in clot formation.
“we expect factor xi to be a safer target for new anticoagulants than the targets of currently available anticoagulants because patients with congenital factor xi deficiency are at reduced risk for clots but rarely have spontaneous bleeding,” he said.